Download PDF
Thromb Haemost 1967; 18(03/04): 544-551
DOI: 10.1055/s-0038-1655064
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Studies on Hypercoagulable State

II. The Application of 131I-Labelled Fibrinogen for the Estimation of Intravascular Coagulation in Human Subjects
G Izak M. D.
1   Department of Medicine B, the Hematology Research Laboratory and the Department of Surgery A, of the Hebrew University-Hadassah Medical School and the Hadassah University Hospital, Jerusalem (Israel)
,
K Galewski
1   Department of Medicine B, the Hematology Research Laboratory and the Department of Surgery A, of the Hebrew University-Hadassah Medical School and the Hadassah University Hospital, Jerusalem (Israel)
,
Z Eyal M. D.
1   Department of Medicine B, the Hematology Research Laboratory and the Department of Surgery A, of the Hebrew University-Hadassah Medical School and the Hadassah University Hospital, Jerusalem (Israel)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The rate of disappearance of 131I-labelled, purified fibrinogen was estimated in 43 human subjects simultaneously with repeated determinations of various other constituents of the coagulation and fibrinolytic systems.

A marked shortening of theT/2 of 131I-labelled fibrinogen was observed in patients with thromboembolic disease, as well as in some patients following extensive surgical procedures, in the absence of clinical signs of occlusive vascular lesions at the time of the study. In some of the latter patients thromboembolic episodes developed subsequently.

The application of the procedures described here in the diagnosis of the so-called hypercoagulable state is discussed.

 

  • References

  • 1 Aas K. A, Gardner F. H. Survival of blood platelets labeled with chromium. J. clin. Invest 37: 1257 1958;
    CrossrefPubMedGoogle Scholar
  • 2 Adelson E, Rheingold J. J, Crosby W. H. Studies on platelets survival by tagging in vivo with P32 . J. Lab. Clin. Med. 50: 570 1957;
    PubMedGoogle Scholar
  • 3 Leeksma C. H. W, Cohen J. A. Determination of the life span of human blood platelets using labelled diisopropyl-fluorophosphate. J. clin. Invest 35: 964 1956;
    CrossrefPubMedGoogle Scholar
  • 4 Izah G, Galewski K. Studies on experimentally induced hypercoagulable state in rabbits. Thrombos. Diathes. hacmorrh. (Stuttg.). 16: 228 1966;
    PubMedGoogle Scholar
  • 5 Zetterquist E, Blombäck B, Carlson L. A, Franzen S. The turnover of I131 labelled fibrinogen in man. p. G: 77. Xth Cong. Int. Soc. Haemat. Stockholm: Ljunghofs Litografiska A. AB; 1964
    Google Scholar
  • 6 Tocantins L. M. The bleeding time. Amer. J. clin. Path. 06: 160 1936;
    PubMedGoogle Scholar
  • 7 Lee R. I, White P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sci. 35: 964 1913;
    PubMedGoogle Scholar
  • 8 Budtz-Olsen O. E. Clot retraction. Blackwell Scientific Publications; Oxford: 1951
    Google Scholar
  • 9 Wintrobe M. M. Clinical Haematology. 299 Henry Kimpton; London: 1961
    Google Scholar
  • 10 Quick A. T. Determination of prothrombin. In: Quick A. J. The physiology and pathology of hemostasis. 125 Lea and Fabiger; Philadelphia: 1951
    Google Scholar
  • 11 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path. 19: 471 1949;
    PubMedGoogle Scholar
  • 12 Stefanini: New on-stage procedure for the quantitative determination of prothrombin and labile factor. Amer. J. clin. Path. 20: 233 1950;
    PubMedGoogle Scholar
  • 13 Alexander B. Clotting factor VII (proconvertin) Synonymy properties and clinical-laboratory aspects. New Engl. J. Med. 260: 1218 1959;
    CrossrefPubMedGoogle Scholar
  • 14 Bachmann F, Duckert F, Koller F. Stewart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg.). 02: 24 1958;
    PubMedGoogle Scholar
  • 15 Ratnoff O. D, Menzie C. A new method for determination of fibrinogen in small samples of plasma. J. Lab. clin. Med. 37: 316 1951;
    PubMedGoogle Scholar
  • 16 Von Kaulla K. N, Schultz R. L. Methods for evaluation of human fibrinolysis. Amer. J. clin. Path. 29: 104 1958;
    PubMedGoogle Scholar
  • 17 Astrujp A. T. The biological significance of fibrinolysis. Lancet II: 565 1956;
    PubMedGoogle Scholar
  • 18 Nestel P. J. A note on platelet adhesiveness in ischemic heart disease. J. clin. Path. 14: 150 1961;
    CrossrefPubMedGoogle Scholar
  • 19 Wright H. P. Venous thrombosis during pregnancy treated with dicoumarin. J. Obstet. Gynaec. Brit. Emp. 58: 273 1951;
    PubMedGoogle Scholar
  • 20 Fearnley G. R. In: Fibrinolysis. 145 Edward Arnold Ltd; London: 1965
    Google Scholar
  • 21 Izak G, Galewski K, Eyal Z. Hypercoagulable state. Proc. IIIrd. Cong. Asian-Pacific Soc. Hemat. Israel J. med. Sci. 1965
    PubMedGoogle Scholar
  • 22 Gajewski Y, Alexander B. Effect of epsilon aminocaproic acid on turnover of labelled fibrinogen. Circ. Res. 13: 432 1963;
    CrossrefPubMedGoogle Scholar